Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
50M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
55.2M
-
Shares change
-
+4.69M
-
Total reported value, excl. options
-
$467M
-
Value change
-
+$30.4M
-
Put/Call ratio
-
2.71
-
Number of buys
-
69
-
Number of sells
-
-46
-
Price
-
$8.47
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) as of Q4 2024
151 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2024.
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.2M shares
.
Largest 10 shareholders include VR Adviser, LLC (6.25M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (4.91M shares), TANG CAPITAL MANAGEMENT LLC (4.89M shares), Frazier Life Sciences Management, L.P. (4.89M shares), Vestal Point Capital, LP (4.77M shares), Capital World Investors (3.37M shares), BlackRock, Inc. (2.86M shares), VANGUARD GROUP INC (2.26M shares), GREAT POINT PARTNERS LLC (1.79M shares), and Boxer Capital Management, LLC (1.59M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.